We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · February 11, 2021

PET-Guided Omission of Radiotherapy in Early-Stage Unfavourable Hodgkin Lymphoma

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
PET-Guided Omission of Radiotherapy in Early-Stage Unfavourable Hodgkin Lymphoma (GHSG HD17): A Multicentre, Open-Label, Randomised, Phase 3 Trial
Lancet Oncol 2021 Feb 01;22(2)223-234, P Borchmann, A Plütschow, C Kobe, R Greil, J Meissner, MS Topp, H Ostermann, J Dierlamm, J Mohm, J Thiemer, M Sökler, A Kerkhoff, M Ahlborn, TV Halbsguth, S Martin, U Keller, S Balabanov, T Pabst, M Vogelhuber, A Hüttmann, M Wilhelm, JM Zijlstra, A Moccia, G Kuhnert, PJ Bröckelmann, B von Tresckow, M Fuchs, B Klimm, A Rosenwald, H Eich, C Baues, S Marnitz, M Hallek, V Diehl, M Dietlein, A Engert

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading